The data presented here are significant in the current landscape of combination therapies involving PEG‐IFN for hepatitis D. In July 2023, the PEG‐IFN Lambda Phase 3 clinical trial was stopped after a safety review by the DSMB due to frequent ALT flares and high numbers of decompensated patients. Here, GPT is linked to hepatitis D virus infection.